Verrica Pharmaceuticals Q2 EPS $(0.21) Up From $(0.32) YoY, Sales $182.00K Down From $214.00K YoY
Portfolio Pulse from Benzinga Newsdesk
Verrica Pharmaceuticals (NASDAQ:VRCA) reported Q2 losses of $(0.21) per share, a 34.38% improvement from $(0.32) per share YoY. However, sales decreased by 14.95% to $182.00K from $214.00K YoY.
August 08, 2023 | 11:51 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Verrica Pharmaceuticals reported improved Q2 losses but a decrease in sales YoY.
While Verrica Pharmaceuticals has managed to reduce its losses YoY, the decrease in sales could be a concern for investors. The mixed results may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100